IL132537A0 - Truncated vegf-related proteins - Google Patents

Truncated vegf-related proteins

Info

Publication number
IL132537A0
IL132537A0 IL13253798A IL13253798A IL132537A0 IL 132537 A0 IL132537 A0 IL 132537A0 IL 13253798 A IL13253798 A IL 13253798A IL 13253798 A IL13253798 A IL 13253798A IL 132537 A0 IL132537 A0 IL 132537A0
Authority
IL
Israel
Prior art keywords
related proteins
truncated vegf
vegf
truncated
proteins
Prior art date
Application number
IL13253798A
Other languages
English (en)
Original Assignee
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics filed Critical Collateral Therapeutics
Publication of IL132537A0 publication Critical patent/IL132537A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13253798A 1997-04-25 1998-04-20 Truncated vegf-related proteins IL132537A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Publications (1)

Publication Number Publication Date
IL132537A0 true IL132537A0 (en) 2001-03-19

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13253798A IL132537A0 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Country Status (10)

Country Link
EP (1) EP0977854A2 (OSRAM)
JP (1) JP2001524828A (OSRAM)
KR (1) KR20010020259A (OSRAM)
CN (2) CN1260835A (OSRAM)
AU (1) AU7250298A (OSRAM)
CA (1) CA2287538A1 (OSRAM)
EA (1) EA199900861A1 (OSRAM)
IL (1) IL132537A0 (OSRAM)
NZ (2) NZ500530A (OSRAM)
WO (1) WO1998049300A2 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CA2322748A1 (en) * 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO1999049882A2 (en) * 1998-03-27 1999-10-07 Eicher Dorothea J Vegf and vegf-c as infant formula supplements
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
JP2002534058A (ja) 1998-09-08 2002-10-15 アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド 脈管内皮成長因子レセプタ一２タンパクの修飾方法およびその使用方法
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2229788T3 (es) * 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
ATE406907T1 (de) 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US6759386B2 (en) 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
WO2002014367A1 (fr) * 2000-08-10 2002-02-21 Center For Advanced Science And Technology Incubation,Ltd. Facteur de croissance chimere de cellules endotheliales vasculaires de type humain
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2003000009A2 (en) 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
AU2002363369B2 (en) 2001-10-15 2008-08-21 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
EP1827494A4 (en) * 2004-11-18 2010-02-17 Wayne Franco COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES
EP2385840A4 (en) * 2009-01-07 2012-12-12 Vegenics Pty Ltd MATERIALS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
CN118546231B (zh) * 2024-06-28 2026-01-30 温州医科大学 一种修复皮肤屏障的vegf改构蛋白及其在植物中表达的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH11500139A (ja) * 1995-03-02 1999-01-06 アムラド・オペレイションズ・プロプライエタリー・リミテッド 新規成長因子およびそれをコードする遺伝子配列
EP0873348A4 (en) * 1995-06-06 2000-11-08 Human Genome Sciences Inc HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR 3

Also Published As

Publication number Publication date
KR20010020259A (ko) 2001-03-15
AU7250298A (en) 1998-11-24
WO1998049300A2 (en) 1998-11-05
JP2001524828A (ja) 2001-12-04
EA199900861A1 (ru) 2000-06-26
EP0977854A2 (en) 2000-02-09
NZ514872A (en) 2005-01-28
CN1260835A (zh) 2000-07-19
CA2287538A1 (en) 1998-11-05
WO1998049300A3 (en) 1999-03-11
NZ500530A (en) 2001-12-21
CN1680442A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
GB9718609D0 (en) Fusion protein
PT1090128E (pt) Polipéptidos dependentes da vitamina k modificados
ZA9810716B (en) Novel polypeptides
ZA9710338B (en) Proteins
IL133582A0 (en) Mammalian neuro-growth factor like protein
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
GB9718110D0 (en) Peptides
GB9700154D0 (en) Peptides
ZA984322B (en) Sucrose-binding proteins
GB9701710D0 (en) Mammalian protein
GB9720784D0 (en) Protein
EP1037898A4 (en) SECRETIED PROTEINS
ZA971900B (en) Modified proteins
AU2002300742A1 (en) Truncated Vegf-related Proteins
HK1023144A (en) Truncated vegf-related proteins
GB9703104D0 (en) Proteins
GB9722727D0 (en) Proteins
GB9707499D0 (en) Proteins
GB9722003D0 (en) Proteins
GB9707822D0 (en) Proteins
GB9700121D0 (en) Proteins
GB9704252D0 (en) Novel protein
GB9714075D0 (en) Novel protein
GB9703850D0 (en) Novel protein